Splenic marginal zone lymphoma medical therapy
|
Splenic marginal zone lymphoma Microchapters |
|
Differentiating Splenic marginal zone lymphoma from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Splenic marginal zone lymphoma medical therapy On the Web |
|
American Roentgen Ray Society Images of Splenic marginal zone lymphoma medical therapy |
|
Directions to Hospitals Treating Splenic marginal zone lymphoma |
|
Risk calculators and risk factors for Splenic marginal zone lymphoma medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1], Associate Editor(s)-in-Chief: Sowminya Arikapudi, M.B,B.S. [2]
Overview
The predominant therapy for splenic marginal zone lymphoma is surgery. Adjunctive radiotherapy, chemotherapy, and biological therapy may be required. The optimal therapy for splenic marginal zone lymphoma depends on the clinical presentation.
Medical Therapy
- The optimal therapy for splenic marginal zone lymphoma depends on the clinical presentation.
- Treatment options for the condition are as under
- Watchful waiting
- It is a slow growing tumor so patients may not need treatment right away unless symptomatic. Asymptomatic patients may be observed every 3-6 months.[1]
- In the pre-rituximab era splenectomy was considered to be the treatment of choice for splenic marginal zone lymphoma and still is performed for its treatment but ritximab is reported to be more beneficial in old age patients with co-morbid conditions.[2]
- Watchful waiting
| Therapy | Description |
|---|---|
| Watchful waiting | People may not need treatment right away unless they have symptoms |
| Splenectomy | Often respond very well when their spleen is removed with surgery |
| Radiation Therapy | When a splenectomy is not an option, external beam radiation therapy to the spleen |
| Chemotherapy | Doesn’t respond well to chemotherapy
|
| Biological therapy | Rituximab may be used alone or in combination with chemotherapy |
References
- ↑ Matutes E, Oscier D, Montalban C, Berger F, Callet-Bauchu E, Dogan A, Felman P, Franco V, Iannitto E, Mollejo M, Papadaki T, Remstein ED, Salar A, Solé F, Stamatopoulos K, Thieblemont C, Traverse-Glehen A, Wotherspoon A, Coiffier B, Piris MA (March 2008). "Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria". Leukemia. 22 (3): 487–95. doi:10.1038/sj.leu.2405068. PMID 18094718.
- ↑ Tsimberidou AM, Catovsky D, Schlette E, O'Brien S, Wierda WG, Kantarjian H, Garcia-Manero G, Wen S, Do KA, Lerner S, Keating MJ (July 2006). "Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone". Cancer. 107 (1): 125–35. doi:10.1002/cncr.21931. PMID 16700034.
- ↑ Splenic marginal zone lymphoma. Canadian Cancer Society. http://www.cancer.ca/en/cancer-information/cancer-type/non-hodgkin-lymphoma/non-hodgkin-lymphoma/types-of-nhl/splenic-marginal-zone-lymphoma/?region=on Accessed on December 23,2015